Oncology
and Radiotherapy©
18(7) 2024: 001-008 • RESEARCH ARTICLE

EGFR mutations in lung cancer: Implications for personalized therapy

Suphiya Parveen[1], Krishan Kumar[2], Praveen Mathur[3]

[1] Department of Genetics, School of Sciences, JAIN (Deemed-to-be University), Karnataka, India
[2] Department of Biotechnology, Parul University, PO Limda, Vadodara, Gujarat, India
[3] Department of Gen Surgery, Jaipur National University, Jaipur, India

ABSTRACT

Objective: The Epidermal Growth Factor Receptor (EGFR) is mutated in 15% of lung adenocarcinomas. Eight percent of instances with altered Anaplastic Lymphoma Kinase (ALK) are caused by lung adenocarcinomas. For tumours of Non-Small Cell Lung Cancer (NSCLC) that are EGFR mutant and ALK translocation positive, Tyrosine Kinase Inhibitor therapy (TKI therapy) has changed treatment and produced a remarkable preventive effect. Unfortunately, TKI resistance always appears to spread. To overcome the resistance, numerous innovative and promising medicines are being studied.

Results: First-line, recognized opposition, and adjuvant treatment is being investigated for NSCLC with EGFR mutation and ALK positivity, along with the therapeutic implications of recent national meetings and beginning research.

Conclusion: There is a signi icant therapeutic advantage to including EGFR TKIs in EGFR mutant NSCLC First Line (FL) therapy. In phase II and III studies, several possible third-generation EGFR TKIs are being examined in the context of acquired resistance. The medicine is better than chemotherapy as an FL treatment for NSCLC with ALK positivity. For NSCLC with established resistance and an ALK-positive test result, cetinib is approved and effective. More study is needed to develop new medications that can combat acquired resistance to TKIs.

Keywords: Epidermal Growth Factor Receptor (EGFR), Non-Small Cell Lung Cancer (NSCLC), Lung Cancer (LC), Anaplastic Lymphoma Kinase (ALK), Small Cell Lung Cancer (SCLC), Tyrosine Kinase Inhibitors (TKIs)

Address for correspondence:

Suphiya Parveen

Department of Genetics, School of Sciences, JAIN (Deemed-to-be University), Karnataka, India

E-mail: suphiya@jainuniversity.ac.in

Word count: 5427 **Tables:** 03 **Figures:** 05 **References:** 30

Received: 06 July, 2024, Manuscript No. OAR-24-140926
Editor Assigned: 09 July, 2024, Pre-QC No. OAR-24-140926(PQ)
Reviewed: 25 July, 2024, QC No. OAR-24-140926(Q)
Revised: 31 July, 2024, Manuscript No. OAR-24-140926(R)
Published: 07 August, 2024, Invoice No. J-140926

INTRODUCTION

Regarding the greatest common kinds of cancer in the world, LC has a high fatality rate. It happens that aberrant cells develop into tumours in lung tissue as a result of unchecked cell growth. Small Cell Lung Cancer (SCLC) and NSCLC are the two main subtypes of lung cancer. The EGFR that is mutated in around 10%-15% of NSCLC patients is one of the major causes of the disease. Some 85% of all occurrences of LC are NSCLC, making it the more prevalent kind. EGFR is disrupted in around 10%-15% of NSCLC patients and represents one of the major causes of the disease [1]. Particular groups, like nonsmokers, have higher rates of mutations in EGFR. Additionally, cancers are more often discovered in individuals with the NSCLC subtype adenocarcinoma. Usually, tumour tissues from a patient are subjected to genetic testing to detect EGFR mutations that might inform therapy choices. These changes cause the EGFR receptors and downstream signalling pathways to become more active, that leads to unregulated cell growth and division [2].

The patients having NSCLC and EGFR mutations are now being treated like never before recognition to specialized therapy. Gefitinib, erlotinib, and Osimertinib are EGFR TKIs that are oral drugs that selectively target the EGFR receptor and impede its activity. The majority of patients ultimately acquire tolerance to EGFR TKIs, although not all patients having EGFR mutations benefit from targeted treatment. Numerous factors, such as the occurrence of additional EGFR mutations, the activation of alternative signalling pathways, and histological change into a different kind of cancer, might contribute to this resistance [3].

The development of a precision medicine strategy for NSCLC was made possible by EGFR mutations that make them susceptible to TKI. Patients having EGFR-mutant LC often have an improved prognosis than those with other kinds of NSCLC [4]. Considering the expansion of therapy possibilities in the clinical context, NSCLC continues to be the leading cause of cancer-related death in both sexes, accounting for over 85% of all LC cases.

Continuous the therapeutic approach for metastatic NSCLC has undergone a significant change as a result of the clinical understanding of the EGFR mutation condition that emerged more than ten years ago [5]. Erlotinib (Er), gefitinib, and afatinib are three EGFR-TKIs that is developed specifically to treat NSCLC with somatic activating EGFR mutations that have

improved survival rates for patients. The generalized selection requirements increase the complicated nature of the detection techniques, and the detection sensitivity limitations always place a limit on the ability to identify particular genetic variants in NSCLC patients [6]. A combination of 2.09 million additional instances and 1.76 million fatal cases of LC in 2018, it is the most frequent disease and the main reason for cancer-related deaths globally. Nearly two-thirds of cases of NSCLC that make up 85% of all LC cases are already metastasizing to distant organs. If there is not enough tissue available for initial diagnosis or disease progression, the NSCLC recommendations advise plasma genotyping [7].

In contrast to conventional tissue sample methods, bronchosopiccryobiopsy enhances the identification frequency of reactivating EGFR mutations in NSCLC. The customized treatment of individuals with advanced tumours will be improved as a result. A prospective study is necessary for the final evaluation since this analysis is retrospective [8].

The paper measured for NSCLC target oncogenic factors that are more common in people who have had just little exposure to tobacco smoking [9]. Despite pre-clinical indications in favour of the drug-biomarker configurations, the information at hand indicates that only a small subset of these combines exhibit clinically meaningful advantages, which are still mostly restricted to patients with lung malignancies linked to low levels of tobacco smoke exposure.

A multidisciplinary expert group was formed with a major emphasis on EGFR testing to provide general recommendations for biomarker evaluation in patients with advanced NSCLC. The expert panel's main recommendation is that all non-squamous NSCLC patients should have thorough reflexive biomarker evaluation at diagnosis with focused next-generation sequencing, regardless of stage [10].

The paper offered intriguing targets and therapy in addition to established treatments for NSCLC with actionable mutations. Address the state of molecular testing procedures in community oncology facilities as well, as this will inform oncologists' treatment decisions for lung cancer [11]. Talk about the situation of molecular testing practices in community oncology centres as well since this will affect the way oncologists treat lung cancer.

The most frequent reason for cancer-related mortality is lung cancer. One major obstacle to treating cancer is drug resistance, and one of the processes generating medical struggle in NSCLC patients is the histological transition from NSCLC to SCLC. Patients with SCLC who have transformed have traits common to both NSCLC and SCLC and yet lack prompt diagnosis and efficient treatment plans [12]. The most effective therapy strategies and pharmaceutical doses may be changed to increase the effectiveness of care and prospects for patients that have advanced EGFR-mutated NSCLC [13].

The paper examined these mutations in Chinese NSCLC patients. In addition, four interesting candidates for druggable EGFR mutations were identified, opening the door to the creation of individualized treatment strategies for individuals carrying mutations. These findings will aid in the development of individualized NSCLC treatment [14].

The trial's primary objectives assessed the practicality, acceptability, and security of the personalized vaccination strategy, while the trial's secondary goals examined tumour-specific immune response and clinical outcomes. 9 patients of the 16 patients with EGFR mutations maintained TKI treatment while also receiving PPV, while seven patients only got PPV [15].

The discussion will be broken up into a few separate subjects, each of that will be based on the methods that allow these substances to exert their effects. To provide the most up-to-date assessment of targeted LC treatments that are now available as well as those that will become accessible shortly. After each segment, they will also provide a summary of the phase I/II clinical study that is presently being conducted for patients with NSCLC [16].

The paper focused on the biology behind the molecular changes that occur in NSCLC, as well as the instruments for diagnosis and therapy options that are available for each targetable change [17]. Utilizing either biopsy taken from tumour tissue or liquid biopsies, rapid and sensitive procedures are required to identify gene changes. Because several diagnostic tools and individualized therapies are now in the process of being developed, molecular biologists, pathologists, and oncologists need to work closely together. Treatment for NSCLC tumours with EGFR mutations and ALK translocation positive has changed as a result of TKI therapy. Unfortunately, TKI resistance inevitably spreads. Innovative and promising medications are being investigated to overcome resistance.

MATERIALS AND METHODS

Small-molecule compounds that target EGFR

First-generation (G1) EGFR inhibitors:

Initial treatment about a new type, gefitinib, an EGFR TKI, targets a receptor's ATP-binding region with specificity. Several preliminary trials that showed uncommon although substantial effects in not selected individuals, it got quick approval in 2003 to benefit individuals with advanced NSCLC. Gefitinib was authorized at the 250 mg daily dosage due to the early studies' failure to identify a recommended level. Rash and GI problems were some of the typical negative consequences seen. In a decision in 2005, FDA withdrew clearance of every patient apart excluding those that were receiving or had formerly benefited from the medicine due to the absence of a meaningful survival advantage as compared to optimal treatment. The following reverse TKI to be authorized for EGFR-mutated NSCLC is erlotinib (Tarceva). It works identically to gefitinib and exhibits many of the same adverse effects. As patients with EGFR mutations, erlotinib is now authorized in the FL context and beyond [18].

Second-generation (G2) EGFR inhibitors:

To get around G1 EGFR TKIs' apparent opposition, G2 EGFR TKIs is developed, but it has not yet been effective. A quinazoline centre found in the second generation of EGFR TKIs irreversibly binds the ATP-binding site, is greater potent, and offers a side-effect profile that is comparable to that of the first generation of the other G2 EGFR TKI to proceed to Phase III clinical investigations is dacomitinib (PF 00299804), that's exclusive to afatinib. In the Phase III study (ARCHER 1050), dacomitinib, that is created by Pfizer, is being contrasted with gefitinib in the FL context after demonstrating significant effects in the populations of EGFR mutants in Phase II investigations [19].

Third-generation (G3) EGFR inhibitors:

The G3 chemicals differ from the earlier generation's quinazoline components to better bind to the EGFR protein that has the T790M mutation. A representative G3 TKI is CO-1686. It is a covalent inhibitor that only affects the T790M mutation and spares the EGFR protein that is wild-type. In addition to its reduced pharmacokinetics, the initially allowed basic composition did not manage to achieve the Maximum Tolerated Dose (MTD) or sustainable plasma levels. Using CO-1686, hydrobromide salt formulations were created to increase bioavailability. This more recent version only caused hyperglycaemia, had better dose ranges, and caused little to no rashes or diarrhoea [20].

The EGFR exons 18 to 24 that are responsible for encoding the EGFR kinases are that discovered that the reported sensitizing alterations were either point mutations or small in-frame deletions. Exon 19 among the most common mutations has deletions that remove the amino acids Leu-Arg-Glu-Ala, that are close to the kinase's active site, and exon 21 insertions that cause the activation loop residue Leu858Arg to be changed (Figure 1).



Fig. 1. Mutations in the tyrosine kinase binding domain of EGFR

EGFR inhibitors' current first-line usage in metastatic settings:

Anin medically enhanced, terminal NSCLC populations, the Phase III IPASS trial's findings in 2009 showed that gefitinib exhibited an extended Progression Free Survival (PFS) than carboplatin paclitaxel as FL treatment. The majority of the patients were female, rarely or very occasionally smokers, and were diagnosed with adenocarcinoma histologically. Evaluating the effect of medication depending on the patient's genotypes is one of the trial's exploratory goals. 60% of the medically enriched population or 437 out of the 1217 patients had tissue that could be genotyped. These individuals all exhibited EGFR mutations [21].

Additionally, in patients using EGFR the normal form of sickness, the PFS was considerably greater in the groups that got carboplatin-paclitaxel compared to that of patients that received gefitinib. It has unequivocally shown that individuals weren't selected solely on clinical preferences and ought not to receive an EGFR TKI in the FL treatment if parents do not have an EGFR mutant-positive illness. Notably, 2/3 of the EGFR mutant assigned to carboplatin afterward got an EGFR TKI. This interaction may explain the lack of treatment-related variations in PFS observed in an EGFR mutant cohort in OS (Table 1).

Tab. 1. EGFR TKI studies conducted in FL environment

Research Arms	Study	No. of patients	Setting	Surviving in general (month)	Free development and continued survival (month)	The average rate of response (%)
Erlotinib	OPTIMAL	80	First-line	NM	15.3	84
Carbopfatin/gemcitabine		74		NM	6.8	38
Erlotinib	EURTAC	79	First-line	20.5	7.4	52.3
Chemotherapy		74		16.4	3.4	12.3
Gefitinib	WJTOG-3405	84	First-line	33.3	7.4	64.1
Cisplatin/docetaxel		84		36.4	6.5	34.4
Gefitinib	IPASS	134	First-line	23.3	9.3	73.4
Carboplatin/paclitaxel		127		20.5	5.2	45.1
Afatinib	LUX-Lung 6	244	First-line	NM	13	68.7
Cisplatin/gemcitabine		120		NM	3.4	25
Afatinib	LUX-Lung 3	228	First-line	NM	11.3	58
Cisplatin/pemetrexed		113		NM	4.7	25
Gefitinib	North Eastern	118	First-line	28.3	8.6	71.5
Carboplatin/paclitaxel	Japan study group	118		25.8	3.2	30.9

Inulin 2011 and 2012, studies like OPTIMAL and EURTAC were published, confirming the PFS advantage of erlotinib over typical chemotherapy in the FL scenario for EGFR mutant NSCLC. Again, to participate in these trials, patients are required to have exon 19 deletions or the exon 21 L858R mutation, both of which are TKI-sensitizing mutations [22].

In a newly published study, the Phase II NEJ005/TCOG0902, individuals with advanced no squamous EGFR-mutated NSCLC that never received chemotherapy were investigated while receiving concurrent chemotherapy and either concurrent or sequential gefitinib. These findings once again imply that concomitant chemotherapy with gefitinib may be a successful FL treatment, despite the OS's infancy. In conclusion, these studies demonstrate that, despite the added toxicity, combination treatment with an EGFR TKI plus chemotherapy may be a successful FL approach [23]. The combo group's rash and bleeding rates were higher, but toxicity seemed to be controllable. Although OS data is still in its infancy, it will be crucial to understand the function of the combo in the FL situation.

EGFR inhibitors in the developed resistance setting:

Quality established resistance to the EGFR TKIs is the main obstacle in the treatment of EGFR TKIs. Numerous widespread acquired resistance mechanisms have been found by investigations looking at patient tumour tissues during resistance. These mutations cause a reduction in affinity for first and G2 TKIs and an increase in affinity for ATP. In a 2011 study, tissue biopsies from 37 patients with drug-resistant EGFR-mutant NSCLC revealed that all of the patients still had the activating mutation with acquired mutations including PIK3CA mutation (5%), MET amplification (5%), EGFR T790M or transformation into SCLC (14%), or amplification (49%). Additionally, a tiny proportion of malignancies experienced the Epithelial Mesenchymal Transition (EMT) (Figure 2).



Fig. 2. Mechanisms of NSCLC acquired resistance to EGFR/ALK TKIs

The other resistance mechanisms are yet unclear. According to certain research, the prevalence of the T790M resistance mutation in the context of acquired resistance might reach 70%. Interestingly, in the absence of EGFR TKI treatment, certain cancers with T790M mutations may gradually lose their resistance mutation, and these tumours would respond to the medicine again. This observation highlights the need for recurrent biopsies as the illness progresses since the results may change the course of the patient's care (Table 2).

Tab. 2. Trials of EGFR TKIs in the set-ting of acquired resistance

Framework	No. of patients	Surviving in general (month)	Progression-free Survival (month)	Study Arms	The average rate of response (%)
Acquired TKI resistance	91	NA	NR	HM61713	28.30%
T790M +	-	-	-	-	-
Acquired TKI resistance	70	NA	NR	CO-1686	56%
Acquired TKI resistance	Ongoing	-	-	Cisplatin/ pemetrexed/ gefitinib Cisplatin/ pemetrexed	-
T790M +	-	-	-	-	-
Acquired TKI resistance	Ongoing	-	-	EGF816	
Acquired TKI resistance	156	NA	NR	AZD9291	62
T790M +	-	-	-	-	-
T790M-	45	-	NM	AZD9291	21

The Numerous trials have shown that EGFR TKI therapy may be maintained after the illness has advanced, either with or without chemotherapy. At the moment, EGFR inhibitors are often used indefinitely if the pace of advancement is modest. One caution while quitting TKI medication is a tumour's fast development in the weeks or months after stopping the EGFR TKI, together with the discovery of a tumour flare [24]. This is due to the gradual evolution of resistance mutations. In 2011, a retrospective review looked at 61 participants from 6 TKI studies. Of the 61 patients, 14 had a clinical flare-up within a median of eight days of stopping the TKI, which required hospitalization or resulted in death. Certain EGFR mutations, such as T790M, L858R, and exon 18 or 19 mutations, were not linked to fever episodes. Preclinical findings using TKI-resistant NSCLC cell lines suggested one potential strategy to reverse this resistance and prevent these disease flare-ups. In the resistant scenario, these trials showed an additional advantage to TKI and chemotherapeutic dosage regimens.

Preclinical studies showed that the combination was effective against L858R and T790Merlotinib-resistant lung cancers; however, neither drug was effective when used alone. There are now plans to conduct a Phase III study in the FL context for patients with EGFR mutant NSCLC that will combine cetuximab and afatinib [25].

The G3 inhibitor in LC trials for mutant EGFR is the aggregate name for these investigations. Other G3 inhibitors are being developed at different levels. A Phase I study (AURA) has looked at AZD9291 every day or a dosage-escalation treatment. Surprisingly, T790M mutant tumours showed an ORR of 64% with an 83% ORR at the 240 mg dosage [26]. The ORR was 23% (95% CI, 12%–39%) for the 43 patients who did not have the EGFR T790M mutation. Phase I/II studies are now being conducted on AP26113, a unique third-generation TKI that recently finished preclinical development. While ALK-mutant people will participate in the majority of the planned studies, a group of patients with T790M+ NSCLC who have had at least one previous TKI will have their response rates examined [27].

EGFR inhibitors used as adjuvants:

In unselected individuals, Gefitinib did not seem to improve survival, and EGFR mutant tumours appeared to have a tendency toward a survival disadvantage (n=15) (OS (HR), 3.16; 95% CI, 0.61-16.45; p=0.15) and Disease-Free Survival (DFS), 1.84; 95% CI, 0.44-7.73). Although these findings are concerning, this study had severe methodological issues due to the premature closure and lack of prospective determination of the EGFR mutation status [28].

When resected EGFR-mutant NSCLC was treated with erlotinib, 2-years DFS rates were 90% as opposed to the 70% expected DFS based on prior control, according to SELECT. Interestingly, EGFR TKI was remained effective at the time of recurrence in individuals who progressed following adjuvant erlotinib treatment. Since OS was not increased by adjuvant EGFR TKI for two years, these studies have brought up the issue of the duration of the treatment. A prospective randomized ALCHEMIST trial may provide a more conclusive response, the effects of adjuvant erlotinib for two years in individuals that have had EGFR mutations removed.

NSCLC with ALK positivity and ALK inhibitors

Crizotinib is an ALK inhibitor of first generation:

Crizotinib (PF-02341066) was the first ALK inhibitor to get FDA approval. Crizotinib is an ATP-competitive kinase inhibitor with an aminopyridine-like structure. The most frequently reported Adverse Events (AEs) were peripheral edoema, nausea, vomiting, diarrhoea, and visual abnormalities. In NSCLC with ROS1 rearrangement, crizotinib is also being tested as a potent MET inhibitor and ROS1 inhibitor.

Novel ALK inhibitors:

Numerous new ALK inhibitors have been created in response to the clinical finding that it was unavoidable for ALK-positive diseases to develop acquired resistance to crizotinib. ALK TKI treatment can be resistant to in the presence of acquired resistance if there are the kinase domain has at least eight ALK point mutations. A few of these mutations include "L1152R, 1151Tins, C1156Y, F1174L, L1196M, S1206Y, G1202R, and G1269A". Targeting these resistant mutations has included developing several techniques that are covered below.

Ceritinib, also known as LDK378, is an oral drug with remarkable performance in crizotinib-resistant conditions. For individuals with tumors resistant to crizotinib or that are intolerant to crizotinib, FDA-approved ceritinib is more effective than crizotinib against mutant ALK protein. There was no rash, but the drug's AEs included nausea, diarrhoea, and transaminitis. It has doses up to 750 mg and an IC50 of 0.2 nM against ALK. A more modern ALK TKI, CH5424802, has been shown to inhibit STAT3 and AKT in addition to preventing ALK autophosphorylation through interactions with the protein's ATP-binding pocket. It has an oral availability and an IC50 for ALK inhibition of 1.9 nM. Another G2 ALK inhibitor is X-396.

Additional methods for addressing ALK-positive illness-es:

Several studies are presently running to see that ALK inhibition and Hsp90 inhibition work together. Furthermore, a number of studies have demonstrated that crizotinib treatment enhances PFS both before and after treatment, and that ALK-positive tumours appear to react to pemetrexed-based therapy. The lack of thymidylate synthase in ALK-positive tumours has been suggested as the source of pemetrexed sensitivity, albeit the specific origin of this sensitivity is uncertain [29].

ALK inhibitors as an adjuvant and first-line treatment for metastatic disease:

Relative to earlier treatment, patients with the ORR for ALK-positive NSCLC was 57%, while in another 33% of patients, the illness progressed, preliminary findings from Phase I research carried out in 2010. Due to the trial's encouraging findings, it was expanded and continued, and 143 more patients were enrolled as a consequence. Having a median PFS of 9.7 months at the period of publication, 143 patients had a response rate of 61%. These findings led to the rapid FDA approval of crizotinib in August 2011 (Table 3).

Tab. 3. ALK inhibitor experiments

Progression-free Survival (month)	Study Arms	No. of patient	Total rate of reaction (%)	Setting	Totality of survival (month)
NM	CH5424802	48	92	Crizotinib naive	NM
NM		33	50	Crizotinib resistant	NM
7.5	Crizotinib	145	62.6	All lines	NM
8.7	Crizotinib	341	72	First-line	NM
5	Cisplatin/ pemetrexed		46		
5.5	Crizotinib	171	63	Second-line	NM
5	Docetaxel or pemetrexed	172	18		NM
9	Ceritinib	116	60	All lines	NM
		78	54	Crizotinib resistant	NM
6.3	Crizotinib	138	58	Second-line and beyond	

Initially, Crizotinib was made to serve as an FL therapy for NSCLC with an ALK optimistic status thanks to the significant Phase III trial PROFILE 1014. An OS improvement trend was seen despite a sizeable fraction of crossovers to the crizotinib arm. Alectinib, also known as CH5 424802, showed an ORR of 93.5% in a Phase II study, and no Grade 4 AEs were noted. Phase III ALEX trial: alectinib versus crizotinib in the FL setting for advanced non-small cell lung cancer with ALK-positive, was motivated by these results [30].

114 NSCLC patients with ALK positivity participated in the Phase I ceritinib investigations that showed an ORR of 58%. Additionally, ASP3026, an ALK inhibitor, and X-396, an ALK/MET/mTOR TKI, are being evaluated in FL settings in early-phase studies. Adjuvant and neoadjuvant crizotinib is also being evaluated in phases I through III ALK-positive NSCLC.

Second-line the context of acquired resistance and ALK inhibitors:

According to the previously mentioned Phase I results, crizotinib was initially approved for use in second-line situations and above. The Phase II PROFILE 1005 study and the decisive Phase III PROFILE 1007 trial later confirmed its efficacy in this setting. Crizotinib and conventional chemotherapy were examined in the second-line environment using the PROFILE 1007 Phase III study. Crizotinib's main goal was met with a median PFS of 7.7 months as opposed to 3.0 months with chemotherapy. There was no change in OS; however, ORR was 65.3 against 19.3%. Sadly, most ALK-positive diseases that are treated with crizotinib ultimately become resistant. ALK-positive NSCLC has been linked to TKI resistance through a number of mechanisms, including overexpression of other kinase pathways like KIT, ALK-amplification, and secondary ATP binding site gatekeeper mutations. In the case of acquired resistance, LDK378 (ceritinib), a second-generation ALK inhibitor, has demonstrated the most promising results.

RESULT ANALYSIS

G1 medicines disrupt tumour-promoting signalling pathways by binding reversibly to the EGFR tyrosine kinase domain. G2 medications are more potent and selective for EGFR than G1 inhibitors. They also block other signalling pathways that support the development of tumours. The T790M resistance mutation, which is frequently present in individuals who have grown resistant to first- and G2 inhibitors, is the target of G3 medicines.

The median follow-up time for the patients that were censored was 31.7 months at the time the data were analysed, and 75% of the patients had passed away. The whole group of patients with an EGFR mutation that was given an EGFR TKI had a median OS of 25.9 months. Despite an average OS of 39.0 months in the G2 TKI group compared to 25.0 months in the G1 TKI group, the results were much enhanced in the SG TKI group (Figures 3 and 4).



Fig. 3. Primary Treatment with G2 TKI *vs.* G1TKI



Fig. 4. Primary treatment with a G2 TKI *vs.* G1 TKI and patients' outcomes according to mutation subtype

According to the subtype of the mutation, subgroup analyses were carried out (Figure 5). Patients that received G2 TKI treatment fared better than those who received G1 TKI treatment. Regression models utilizing the propensity score only retained a tendency toward significance. Nevertheless, there was no survival difference between a G1 and a second-generation EGFR TKI. The median OS was 25.4 months, whereas the subset of patients with a L858R variation was studied as opposed to 20.6 months. The HR was 0.90. Patients with uncommon EGFR mutations did not appear to have different survival outcomes when treated with second- and G1 TKI.



Fig. 5. First- and second-line TKI treatment for EGFR detection, G3 TKIs were made available

In 10 (10/15; 67%) instances, the EGFR T790M mutation was deleted. These cases comprised three L858R mutation cases and seven deletions in 19 cases. Five instances, four of which had deletion 19 and one that involved the L858R EGFR gene mutation, maintained the T790M mutation. Osimertinib therapy lasted between 8 and 15 months before progression was seen. Early resistance was seen in T790M-loss patients (6.9 months *vs.* 12.6 months mean, P 14 0.0024 ;).

CONCLUSION

The cell surface protein EGFR is involved in cell growth and division signalling pathways. Mutations in the EGFR gene may cause overproduction of the EGFR protein that encourages LC cell proliferation. Targeted medicines that block the EGFR pathway may delay or halt LC cell proliferation in people with these mutations. FL therapy with an ALK TKI for ALK-positive illnesses and an EGFR TKI for EGFR mutant disorders is unquestionably more effective and much less harmful than traditional cytotoxic chemotherapy. A number of recognized resistance pathways exist, and acquired resistance is inevitable in both of these oncogene-driven malignancies. The creation of tailored drugs that can combat TKI resistance brought on by gatekeeper mutations has advanced significantly. To create efficient defences against the other known acquired resistance mechanisms, further research is needed. It is yet unclear how these targeted drugs should be used as adjuvants. EGFR-targeted LC medicines cause medication resistance. These medicines initially suppress cancer cell proliferation, but certain cancer cells evolve mutations that render them resistant. Even with therapy, the cancer may develop and spread. Cell growth and division depend on cell surface EGFR. EGFR gene mutations may cause uncontrolled cell proliferation and lung cancer.

REFERENCES

1. Aggarwal C, Thompson JC, Black TA, Katz SI, Fan R, et al. Clinical implications of plasma-based genotyping with the delivery of personalized therapy in metastatic non–small cell lung cancer. JAMA Oncol. 2019; 5:173-180.
2. Wang M, Herbst RS, Boshoff C. Toward personalized treatment approaches for non-small-cell lung cancer. Nat Med. 2021; 27:1345-1356.
3. Li W, Liu JB, Hou LK, Yu F, Zhang J, et al. Liquid biopsy in lung cancer: significance in diagnostics, prediction, and treatment monitoring. Mol Cancer. 2022; 21:25.
4. Buttitta F, Felicioni L, Di Lorito A, Cortellini A, Irtelli L, et al. Early prediction of resistance to tyrosine kinase inhibitors by plasma monitoring of EGFR mutations in NSCLC: A new algorithm for patient selection and personalized treatment. Oncotarget. 2020; 11:982.
5. Gristina V, Malapelle U, Galvano A, Pisapia P, Pepe F, et al. The significance of epidermal growth factor receptor uncommon mutations in non-small cell lung cancer: A systematic review and critical appraisal. Cancer Treat Rev. 2020; 85:101994.
6. Zhang Y, Zhang L, Lin X, Ke L, Li B, et al. Dual-responsive nanosystem for precise molecular subtyping and resistant reversal of EGFR targeted therapy. Chem Eng J. 2019; 372:483-495.
7. Deng Q, Fang Q, Sun H, Singh AP, Alexander M, et al. Detection of plasma EGFR mutations for personalized treatment of lung cancer patients without pathologic diagnosis. Cancer Med. 2020; 9:2085-2095.
8. Haentschel M, Boeckeler M, Ehab A, Wagner R, Spengler W, et al. Cryobiopsy increases the EGFR detection rate in non-small cell lung cancer. Lung Cancer. 2020; 141:56-63.
9. Middleton G, Fletcher P, Popat S, Savage J, Summers Y, et al. The National Lung Matrix Trial of personalized therapy in lung cancer. Nature. 2020; 583:807-812.
10. Cheema PK, Gomes M, Banerji S, Joubert P, Leighl NB, et al. Consensus recommendations for optimizing biomarker testing to identify and treat advanced EGFR-mutated non-small-cell lung cancer. Curr Oncol. 2020; 27:321-329.
11. Rajurkar S, Mambetsariev I, Pharaon R, Leach B, Tan T, et al. Non-small cell lung cancer from genomics to therapeutics: A framework for community practice integration to arrive at personalized therapy strategies. J Clin Med. 2020; 9:1870.
12. Chai X, Zhang X, Li W, Chai J. Small cell lung cancer transformation during antitumor therapies: A systematic review. Open Med (Wars). 2021; 16:1160-1167.
13. Solassol I, Pinguet F, Quantin X. FDA-and EMA-approved tyrosine kinase inhibitors in advanced EGFR-mutated non-small cell lung cancer: safety, tolerability, plasma concentration monitoring, and management. Biomolecules. 2019; 9:668.
14. Meng H, Guo X, Sun D, Liang Y, Lang J, et al. Genomic profiling of driver gene mutations in Chinese patients with non-small cell lung cancer. Front Genet. 2019; 10:1008.
15. Li F, Deng L, Jackson KR, Talukder AH, Katailiha AS, et al. Neoantigen vaccination induces clinical and immunologic responses in non-small cell lung cancer patients harboring EGFR mutations. J Immunother Cancer. 2021;9.
16. Majeed U, Manochakian R, Zhao Y, Lou Y. Targeted therapy in advanced non-small cell lung cancer: current advances and future trends. J Hematol Oncol. 2021; 14:1-20.
17. Pinsolle J, McLeer-Florin A, Giaj-Levra M, De Fraipont F, Emprou C, et al. Translating systems medicine into clinical practice: examples from pulmonary medicine with genetic disorders, infections, inflammations, cancer genesis, and treatment implication of molecular alterations in non-small-cell lung cancers and personalized medicine. Front Med (Lausanne). 2019; 6:233.
18. Rangachari D, T. C, Shpilsky JE, VanderLaan PA, Kobayashi SS, et al. EGFR-mutated lung cancers resistant to osimertinib through EGFR C797S respond to first-generation reversible EGFR inhibitors but eventually acquire EGFR T790M/C797S in preclinical models and clinical samples. J Thorac Oncol. 2019; 14:1995-2002.
19. Lau SC, Chooback N, Ho C, Melosky B. Outcome differences between first-and SG EGFR inhibitors in advanced EGFR mutated NSCLC in a large population-based cohort. Clin Lung Cancer. 2019; 20.
20. Shi K, Wang G, Pei J, Zhang J, Wang J, et al. Emerging strategies to overcome resistance to third-generation EGFR inhibitors. J Hematol Oncol. 2022; 15:1-44.
21. Shah R, Lester JF. Tyrosine kinase inhibitors for the treatment of EGFR mutation-positive non–small-cell lung cancer: A clash of the generations. Clin Lung Cancer. 2020; 21.
22. Kassem L, Shohdy KS, Lasheen S, Abdel-Rahman O, Ali A, et al. Safety issues with the ALK inhibitors in the treatment of NSCLC: a systematic review. Crit Rev Oncol Hematol. 2019; 134:56-64.
23. Ziad A, Abdurahman A, Misako N. A comprehensive review on antibody-drug conjugates (ADCs) in the treatment landscape of non-small cell lung cancer (NSCLC). Cancer Treat Rev. 2022; 102393.
24. Wang J, Xu B. Targeted therapeutic options and future perspectives for HER2-positive breast cancer. Signal Transduct Target Ther. 2019; 4:34.
25. Yang F, Zhang W, Shang X, Liu N, Ma X, et al. Comparison of the efficacy and safety of first-line treatments based on clinicopathological characteristics for patients with advanced epidermal growth factor receptor mutated non-small-cell lung cancer: A systematic review and network meta-analysis. Crit Rev Oncol Hematol. 2022; 103760.
26. Yi L, Fan J, Qian R, Luo P, Zhang J. Efficacy and safety of osimertinib in treating EGFR-mutated advanced NSCLC: A meta-analysis. Int J Cancer. 2019; 145:284-294.
27. Kawashima Y, Fukuhara T, Saito H, Furuya N, Watanabe K, et al. Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Respir Med. 2022; 10:72-82.
28. Stinchcombe TE, Jänne PA, Wang X, Bertino EM, Weiss J, et al. Effect of erlotinib plus bevacizumab vs erlotinib alone on progression-free survival in patients with advanced EGFR-mutant non–small cell lung cancer: a phase 2 randomized clinical trial. JAMA Oncol. 2019; 5:1448-1455.
29. Wu YL, Cheng Y, Zhou J, Lu S, Zhang Y, et al. Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial. Lancet Respir Med. 2020; 8:1132-1143.
30. Sun L, Guo YJ, Song J, Wang YR, Zhang SL, et al. Neoadjuvant EGFR-TKI therapy for EGFR-mutant NSCLC: a systematic review and pooled analysis of five prospective clinical trials. Front Oncol. 2021; 10:586596.